The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine model.
BALB/c mice were pretreated intraperitoneally with interleukin-1 (IL-1) and sonicated tumor extract (SE) from plasmacytoma MOPC104E, 10, 7, and 4 days prior to the intraperitoneal or subcutaneous inoculation of MOPC104E cells, following which significant suppression was observed. The mean survival time and tumor diameter on day 21 were 46.7 days and 0 mm, respectively, in contrast to the 20.9 days and 20.4 mm of control mice. Mice pretreated with IL-1 and SE from MOPC104E (MOPC-SE) were not suppressed following fibrosarcoma MethA inoculation, which indicates the tumor specificity of immunity in this model. This systemically operating antitumor immunity was also achieved by the intramuscular administration of IL-1, or when tumor challenge was performed on day 7 or 14. Moreover, MOPC104E-specific delayed-type hypersensitivity was detected in these mice. The results of this study suggest the possibilities of a new type of active specific immunotherapy, which could prove useful as postsurgical adjuvant therapy for cancer patients.
Harada
T
T
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Kan
N
N
Okino
T
T
Ichinose
Y
Y
Moriguchi
Y
Y
Li
L
L
Sugie
T
T
Ohgaki
K
K
Imamura
M
M
D000818:Animals; D004195:Disease Models, Animal; D006968:Hypersensitivity, Delayed; D016233:Immunotherapy, Active; D007375:Interleukin-1 / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000008:administration & dosage* / Q000302:isolation & purification; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D010954:Plasmacytoma / Q000737:chemistry* / Q000628:therapy*; D014407:Tumor Cells, Cultured
D007375:Interleukin-1; D009363:Neoplasm Proteins